SOPHIA ANTIPOLIS CEDEX, FRANCE--(Marketwire - August 28, 2012) - www.nicox.com
NicOx S.A. (EURONEXT PARIS: COX) today announced the strengthening of its
United States (US) business operations with the appointment of three
commercial executives at NicOx Inc., its US subsidiary. These
appointment of Jerry St. Peter as Executive Vice President and General
of NicOx Inc. in March 2012.
NicOx is building up its commercial organization in the US and in
following the recent in-licensing of AdenoPlus™, a rapid point-of-care
for the detection of adenoviral conjunctivitis, which is already
marketing in the US and Europe. The launch in both markets is expected to
place later this year and will be supplemented in the future by other
products, both diagnostic and therapeutic, that the Company plans to
Jason Menzo has been appointed Director of Marketing for NicOx Inc. Mr.
will be responsible for leading the overall marketing strategy,
product positioning, branding, messaging and support for the sales
enable maximum brand equity. Mr. Menzo has a 15-year track record in
marketing, training and operations. In his most recent role, Mr.
Senior Brand Manager for the PureVision® portfolio of contact lenses
at Bausch +
Lomb. Previously, he was Associate Director of Marketing at
Pharmaceuticals, Inc., an ophthalmic-focused company acquired by Merck &
May 2011. In that role, he led the marketing of AzaSite®,
Elestat®, and co-promotion activities for Restasis®. He also
played an integral role in
ophthalmic business development product evaluations and assessments.
Mark Puwal has been appointed National Director of Sales for NicOx,
will lead the new sales organization in the US. Mr. Puwal has 19
pharmaceutical and medical device management and leadership experience in
sales, sales management, commercial training and development, and
markets. Before joining NicOx, he was Regional Sales Director at
Biomedical. Prior to that, he was National Sales Director at
Pharmaceuticals, Inc. where he was directly involved in the build out
ophthalmic sales organization to 100 Territory Managers and Regional
Mr. Puwal and his team successfully launched the ophthalmic products
and AzaSite® and played an integral role in the successful co-
for Restasis®, resulting in seven consecutive years of double
growth to $125 million before Inspire was acquired by Merck & Co in May
Jason Werner has been appointed Director of Commercial Development &
Alliances for NicOx Inc. Mr. Werner will oversee the strategic
commercial development of current and future products. Mr. Werner brings
12 years of commercial strategy and global market development experience in
sciences and technology. In his most recent role at Wipro Limited as
Principal, he led the Global Domain Consulting Practice in the Life
Division, focused on commercial solutions. Prior to Wipro, Mr.
Associate Director, Strategic Product Planning, at Inspire
Inc., where he led global commercial planning for the cystic fibrosis
In addition, Mr. Werner held positions in sales and marketing for
entry into the ophthalmic arena.
"I am very pleased to welcome Jason Menzo, Mark Puwal and Jason Werner
team in the US and I am confident that their expertise will be
helping NicOx's development into an international specialty ophthalmic
said Jerry St. Peter, Executive Vice President and General Manager of NicOx
"This is a crucial time for NicOx as we prepare our commercial
the United States for the launch of our first product, AdenoPlus™, by
of the year. These appointments will also greatly enhance our
identify and acquire additional ophthalmic products in the US, which will
us to fully leverage our future specialized sales force."
NOTE: AzaSite® is a registered trademark of InSite Vision Inc. and
to Merck and Company; Elestat® is a registered trademark of Boehringer
International GmbH and is licensed to Allergan, Inc.;
PureVision® is a
registered trademark of Bausch + Lomb and Restasis® is a registered
NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating an international,
stage development and commercial ophthalmology group based around
diagnostics and devices.
NicOx has in-licensed innovative ocular diagnostics from RPS®,
AdenoPlus™, a test for the detection of adenoviral conjunctivitis
authorized for marketing in the United States and Europe. The Company
partnership with Bausch + Lomb for the development of BOL-303259-X, a
glaucoma candidate based on NicOx's proprietary nitric oxide-
Further nitric oxide-donating compounds are under development in
ophthalmology indications notably through partners, including Merck
MSD outside the United States and Canada) and Ferrer.
NicOx S.A. is headquartered in France and is listed on Euronext
(Compartment C: Small Caps).
This press release contains certain forward-looking statements.
Company believes its expectations are based on reasonable assumptions,
forward-looking statements are subject to numerous risks and
which could cause actual results to differ materially from those
the forward-looking statements.
Risks factors which are likely to have a material effect on NicOx's
presented in the 4(th) chapter of the « Document de
référence, rapport financier
annuel et rapport de gestion 2011 » filed with the French
Autorité des Marchés
Financiers (AMF) on February 29, 2012 and available on NicOx's
(www.nicox.com) and on the AMF's website (www.amf-france.org).
NicOx strengthens US commercial team:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE